NEWS ROOM

See the latest news from our company below or use the search feature. For more information, contact our head office or the Marketing Communications Manager directly at marcom@arazygroup.com.


 

FDA EXTENDS UDI COMPLIANCE DEADLINES FOR LOW-RISK MEDICAL DEVICES

by Arazy Group | Jun 08, 2017
The US Food and Drug Administration (FDA) has extended the compliance deadlines for the unique device identification (UDI) system requirements for certain class I and unclassified medical devices from September 24, 2018 to September 24, 2020.

UDI requirements for class III; implantable, life-supporting or life-sustaining (I/LS/LS); and class II devices have already been implemented by the FDA and industry. Numerous device labels now display UDIs, and the FDA’s Global Unique Device Identification Database, GUDID, is already a large repository of device identification information.

The FDA plans to engage with industry and other stakeholders to address existing challenges associated with implementing UDI and optimize the quality and utility of the data for higher-risk medical devices already in GUDID before adding lower-risk medical devices.

In order to extend the compliance dates for lower-risk medical devices, the FDA intends to issue a guidance document to provide an enforcement discretion policy for labeling, GUDID data submission, standard date formatting and direct mark requirements for certain class I and unclassified devices. This enforcement discretion policy will not apply to class I or unclassified implantable, life-supporting or life-sustaining devices as labelers of these devices must already comply with UDI requirements.    

Contact us today for more information on the UDI requirements and to discover how regulatory intelligence and registration management system LICENSALE.COM® assists MedTech firms in gaining access to 100+ markets faster and more cost-effectively than ever before.
 
 
 
 

 

Back to Press Room

latest news
  • Jun 12 2018
    REGULATORY UPDATE - SYNTHETIC MR

    USA: Synthetic MR's SyMRI for Phillips was approved for sale with LICENSALE.COM®. ...

    Read More
  • Jun 12 2018
    REGULATORY UPDATE - TECHNOPATH CLINICAL DIAGNOSTICS

    Italy: Technopath Clinical Diagnostics' Multichem QC was approved for sale with LICENSALE.COM®. ...

    Read More
  • Jun 7 2018
    REGULATORY UPDATE - SPD

    Philippines: SPD's IVD Products for CB11 were approved for sale with LICENSALE.COM®....

    Read More
  • May 29 2018
    REGULATORY UPDATE - ORASURE TECHNOLOGIES

    Burundi: OraSure Technologies' HIVST test kit was approved for sale with LICENSALE.COM®....

    Read More
  • May 25 2018
    JOB POSTING: SOFTWARE ENGINEER/DEVELOPER (STUDENT)

    Arazy Group Consultants Inc. is currently seeking qualified applicants for the position of Software Engineer/Developer. The incumbent will participate in the development and integration of machine learning and gamification within a SaaS application....

    Read More

VANCOUVER OFFICE

  • Phone +1 604.681.6888
  • Fax +1 604.681.6822
  • info@arazygroup.com
  •  
  • #350-1333 Johnston Street
  • Pier 32, Granville Island
  • Vancouver, British Columbia
  • Canada V6H 3R9

BACK TO TOP